CIBC World Keeps Sector Perform on Neurocrine

Analyst Matt Geller says the drugmaker plans an earlier-than-expected filing for its insomnia drug

CIBC World keeps the sector perform rating on Neurocrine Biosciences (NBIX ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.